Sphera Funds Management LTD. Buys 200,000 Shares of Immatics (NASDAQ:IMTX)

Sphera Funds Management LTD. increased its holdings in Immatics (NASDAQ:IMTX - Free Report) by 27.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 921,111 shares of the company's stock after purchasing an additional 200,000 shares during the quarter. Immatics accounts for 1.2% of Sphera Funds Management LTD.'s holdings, making the stock its 28th biggest position. Sphera Funds Management LTD. owned about 0.77% of Immatics worth $6,549,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in IMTX. abrdn plc raised its holdings in shares of Immatics by 49.2% in the 4th quarter. abrdn plc now owns 347,379 shares of the company's stock worth $2,470,000 after purchasing an additional 114,479 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Immatics during the fourth quarter valued at approximately $211,000. Platinum Investment Management Ltd. raised its holdings in shares of Immatics by 53.1% during the fourth quarter. Platinum Investment Management Ltd. now owns 311,722 shares of the company's stock valued at $2,216,000 after acquiring an additional 108,108 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Immatics by 24.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company's stock valued at $163,000 after acquiring an additional 4,477 shares during the period. Finally, Schroder Investment Management Group raised its holdings in shares of Immatics by 52.6% during the fourth quarter. Schroder Investment Management Group now owns 427,994 shares of the company's stock valued at $2,953,000 after acquiring an additional 147,547 shares during the period. 64.41% of the stock is currently owned by institutional investors.

Immatics Price Performance

Shares of NASDAQ IMTX traded up $0.55 during trading hours on Monday, hitting $5.29. 1,108,585 shares of the stock were exchanged, compared to its average volume of 657,544. The company's 50 day moving average is $4.48 and its 200 day moving average is $5.82. The firm has a market capitalization of $643.00 million, a P/E ratio of -8.02 and a beta of 0.87. Immatics has a one year low of $3.30 and a one year high of $13.77.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. The business had revenue of $20.12 million during the quarter, compared to the consensus estimate of $14.92 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. Research analysts anticipate that Immatics will post -0.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an "overweight" rating on shares of Immatics in a research report on Tuesday, April 1st.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.